* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Atorvastatin
Discovery and development of integrase inhibitors wikipedia , lookup
Discovery and development of direct Xa inhibitors wikipedia , lookup
Discovery and development of direct thrombin inhibitors wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Pharmacognosy wikipedia , lookup
Neuropharmacology wikipedia , lookup
Drug design wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of neuraminidase inhibitors wikipedia , lookup
Prescription costs wikipedia , lookup
Metalloprotease inhibitor wikipedia , lookup
Plateau principle wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Drug interaction wikipedia , lookup
Theralizumab wikipedia , lookup
Discovery and development of cyclooxygenase 2 inhibitors wikipedia , lookup
Atorvastatin Lipitor™ LIPITOR TABLETS(TAB FILM C 20 mg ) [1 of 3] [ Indications/Dosage ] [ Administration ] [ Contraindications/Precautions ] [ Interactions ] [ Adverse Reactions ] [ Patient Education ] [ Costs ] [ Product Info ] [ Classification ] [ Chemical Structures] -------------------------------------------------------------------------------Description: Atorvastatin is a selective, competitive HMG-CoA reductase inhibitor. Atorvastatin is primarily used to lower cholesterol and triglycerides in patients with hypercholesterolemia and mixed dyslipidemia. At the maximum recommended dosage, atorvastatin has greater LDLlowering efficacy relative to the maximum recommended dosage of other HMG-CoA reductase inhibitors. In a dose-dependent manner, atorvastatin lowers LDL cholesterol by as much as 60%; doses as low as 2.5 mg/day were as effective as lower doses of other HMG-CoA reductase inhibitors.[1378] Atorvastatin doses of 10—80 mg once daily result in mean LDL reductions ranging from 43—60%. Triglycerides are lowered in patients with hypertriglyceridemia by as much as 45%[1379] and HDL cholesterol increases by as much as 12% with atorvastatin monotherapy. The combination of atorvastatin and colestipol produced a 10% greater reduction in LDL-cholesterol than atorvastatin alone, however, adverse reactions were greater and compliance was lower for the combination.[1380] Atorvastatin's unique structure, long half-life, and hepatic selectivity may explain its greater LDL-lowering potency compared to other HMGCoA reductase inhibitors. Atorvastatin may also be used in the treatment of homozygous familial hypercholesterolemia. Final FDA approval for atorvastatin was granted on December 18, 1996. Mechanism of Action: Atorvastatin is a selective, competitive inhibitor of hydroxymethylglutarylcoenzyme A (HMG-CoA) reductase. HMG-CoA reductase is the rate-limiting hepatic enzyme responsible for converting HMG-CoA to mevalonate, a precursor of sterols including cholesterol. Inhibition of HMG-CoA reductase lowers the amount of mevalonate and subsequently reduces cholesterol levels in hepatic cells. This, in turn, results in upregulation of LDL-receptors and increased hepatic uptake of LDL-cholesterol from the circulation. Atorvastatin ultimately reduces the levels of circulating total cholesterol, LDL-cholesterol, and serum triglycerides. Drug dosage rather than systemic drug concentration correlates better with LDL-cholesterol reduction. As with other HMG-CoA reductase inhibitors, atorvastatin exhibits no effects on antipyrine hepatic metabolism.[1381] HMG-CoA reductase inhibitors have been reported to decrease endogenous CoQ10 serum concentrations; the clinical significance of these effects is unknown. Pharmacokinetics: Atorvastatin is administered orally. Following oral administration, the drug is rapidly absorbed with peak plasma concentrations occurring within 1—2 hours. The extent of absorption increases in proportion to the dose of atorvastatin. The absolute bioavailability is approximately 14% and the systemic availability of HMG-CoA reductase inhibitory activity is approximately 30%. Presystemic clearance and/or hepatic first-pass metabolism accounts for the low systemic bioavailability. Food decreases the rate and extent of atorvastatin absorption by approximately 25% and 9%, respectively, however, LDL-cholesterol reduction is similar whether the drug is given with or without food. Similarly, atorvastatin plasma concentrations are lower following evening doses compared with morning dosing and LDL-cholesterol reduction is the same regardless of the time of day the drug is administered. Atorvastatin plasma concentrations are higher in healthy elderly patients than in young adults, however, LDL-cholesterol reduction is comparable. Atorvastatin is >= 98% bound to plasma proteins. A blood/plasma ratio of 0.25 indicates poor drug penetration into red blood cells. Animal data reveal that atorvastatin is likely to be secreted in human milk. Atorvastatin undergoes extensive metabolism to active ortho- and parahydroxylated metabolites which account for approximately 70% of the circulating HMG-CoA reductase inhibitory activity. Based on in vitro studies, cytochrome P450 3A4 may also contribute to the metabolism of atorvastatin. In animals, the ortho-hydroxy metabolite is further metabolized by glucuronidation. Elimination of atorvastatin and its metabolites occurs primarily in bile following hepatic and/or extrahepatic metabolism. It does not appear that the drug undergoes enterohepatic recirculation. Less than 2% of a dose is recovered in the urine following oral administration. The mean plasma elimination half-life of atorvastatin in humans is approximately 14 hours, however, the half-life of HMG-CoA reductase inhibitory activity is 20—30 hours because of the active metabolites. Plasma concentrations of atorvastatin are higher (about 40% for Cmax and 30% for AUC) in healthy elderly subjects than in young adults. In addition, the LDL-cholesterol reduction is also greater that seen in younger patient populations given equivalent doses atorvastatin. [ Revised 2/18/02 ] -------------------------------------------------------------------------------Clinical Pharmacology 2000 Copyright © 2002 Gold Standard Multimedia VERSION 2.04 (2nd Quarter, 2002)